Sunshine Biopharma (SBFM)

• Market cap: $6.48M
• 1 day: 8.00%
• 5 days: 20.00%
• 1 month: 32.79%
• 3 months: 6.93%
• 6 months: -53.71%
• Year to date: -99.41%
• 1 year: -99.44%
• 5 years: -99.93%
• 10 years: -99.93%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.

Employees: 44

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

24% more capital invested

Capital invested by funds: $90K [Q2] → $111K (+$21.3K) [Q3]

1.72% more ownership

Funds ownership: 1.15% [Q2] → 2.87% (+1.72%) [Q3]

9% less funds holding

Funds holding: 11 [Q2] → 10 (-1) [Q3]

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 363% upside
• Avg. target: $15 363% upside
• High target: $15 363% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Aegis Capital David Bouchey 0% 1-year accuracy 0 / 1 met price target

363% upside $15

Buy Reiterated

5 Dec 2024